Ingevity - NGVT Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ingevity in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NGVT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NGVT, but not buy additional shares or sell existing shares.
View NGVT analyst ratings or view top-rated stocks.

2 Wall Street research analysts have issued twelve-month target prices for Ingevity's shares. Their NGVT share price forecasts range from $81.00 to $84.00. On average, they expect the company's stock price to reach $82.50 in the next year. This suggests a possible upside of 27.8% from the stock's current price.
View analysts price targets for NGVT or view top-rated stocks among Wall Street analysts.

Ingevity's stock was trading at $71.70 on January 1st, 2022. Since then, NGVT shares have decreased by 10.0% and is now trading at $64.53.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 26th 2022.
View our NGVT earnings forecast.

Ingevity Co. (NYSE:NGVT) issued its quarterly earnings data on Tuesday, August, 2nd. The company reported $1.73 earnings per share for the quarter, beating analysts' consensus estimates of $1.68 by $0.05. The business earned $419.90 million during the quarter, compared to analyst estimates of $406.50 million. Ingevity had a net margin of 9.61% and a trailing twelve-month return on equity of 33.97%.

Ingevity issued an update on its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.52 billion-$1.65 billion, compared to the consensus revenue estimate of $1.59 billion.

2 employees have rated Ingevity Chief Executive Officer John Fortson on Glassdoor.com. John Fortson has an approval rating of 100% among the company's employees. This puts John Fortson in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ingevity investors own include Pfizer (PFE), AbbVie (ABBV), General Electric (GE), Verizon Communications (VZ), WestRock (WRK), Abbott Laboratories (ABT), Boeing (BA), Costco Wholesale (COST), Dominion Energy (D) and Johnson & Johnson (JNJ).

Ingevity trades on the New York Stock Exchange (NYSE) under the ticker symbol "NGVT."

Shares of NGVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NGVT stock can currently be purchased for approximately $64.53.

Ingevity (NYSE:NGVT) has a market capitalization of $2.50 billion and generates $1.39 billion in revenue each year. The company earns $118.10 million in net income (profit) each year or $3.72 on an earnings per share basis.

The company employs 1,850 workers across the globe.

Ingevity's mailing address is 4920 O`Hear Avenue Suite 400, North Charleston SC, 29406. The official website for the company is www.ingevity.com. The company can be reached via phone at (844) 643-8489, via email at daniel.gallagher@ingevity.com, or via fax at 843-740-8165.